John Reed, Sanofi R&D chief (Jeff Rumans)

Am­i­cus shares surge as Sanofi strug­gles to raise a cheer for mixed piv­otal da­ta for a PhI­II con­tender — and an­a­lysts blow a rasp­ber­ry

Sanofi took ex­tra time on Tues­day to of­fer an up­beat as­sess­ment of its top-line re­sults for a piv­otal study of a new ERT for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.